Salvatore Brugaletta: Is Twelve Months of DAPT Still Too Long After ACS?
Salvatore Brugaletta, Associate Professor of Medicine at University of Barcelona, shared on LinkedIn about a recent article he and his colleagues co-authored, published in BMJ Heart, adding:
”Twelve months DAPT starts to be too long as compared to a strategy of short DAPT in ACS patients.
While earlier aspirin discontinuation may be associated with greater net clinical benefit owing to reduced bleeding, 3- month DAPT may be associated with more favourable ischaemic outcomes, underscoring the importance of individualising DAPT duration according to bleeding and ischaemic risk.”
Title: Optimal timing of aspirin discontinuation after acute coronary syndrome treated with percutaneous coronary intervention: a systematic review and meta-analysis
Authors: Kamil Bujak, Claudio Laudani, Riccardo Rinaldi, Paweł Łajczak, Mariusz Gąsior, Natalia Pawlas, Luis Ortega-Paz, Manel Sabate, Salvatore Brugaletta
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 30, 2026, 02:55Edward Lee Carter: How A Landmark Stewardship Shift Reduced Unnecessary Antiplatelet Use Across VISN 8
-
Jun 30, 2026, 02:43Nicolas Gendron: More than a Research Fellowship – Leaving the Wagner Lab
-
Jun 30, 2026, 02:29Wolfgang Miesbach: Can We ‘Pre‑Tame’ the Immune System to Unlock Better AAV8 FVIII Expression?
-
Jun 30, 2026, 02:21Mohammad Khalil: Evaluating DAPT Duration after Percutaneous Coronary Intervention
-
Jun 30, 2026, 02:11Rishdha Roshad: Activated Clotting Time – Adult vs Pediatric
-
Jun 30, 2026, 02:02Julia Castillo González: Role of Cortistatin During the Acute and Subacute Phases of Ischemic Stroke
-
Jun 29, 2026, 23:26Sandy Middleton: The 2026 Stroke Clinical Care Standard Has Arrived with Nursing Leadership at Its Core
-
Jun 29, 2026, 22:14To Continue or Interrupt DOAC Therapy? The Evidence Remains Unclear – RPTH Journal
-
Jun 29, 2026, 20:09Mamta Soni: The Role of Anti-Xa Monitoring in Anticoagulation Management